Sponsored by Winsantor, The University of Alberta and other research institutes are conducting a randomized outpatient, double-blind, placebo-controlled, multiple-site study of the safety, tolerability, and exploratory efficacy of topically administered WST-057 (4% pirenzepine free base monohydrate) for 24 weeks in subjects with T2DM with peripheral neuropathy. Inclusion criteria include: diagnosis of T2DM; age rage 18-75 years, and presence of definite diabetic neuropathy of at least 12 months duration in the lower extremities. For more information including the full list of criteria, click here.
If you fit the criteria and are interested in participating in this study, please contact:
|Angela Hansen||858 848 email@example.com|
|Stan Kim||858 336 firstname.lastname@example.org|
Search the Government of Canada’s clinical trial database
The Muscular Dystrophy Association of Canada’s list of clinical trials
The National Library of Medicine (NLM) provides a regularly updated, online database of clinical trials around the world